Hytera Group Harvests Five Prestigious ICCA Awards for Innovations and Market Excellence
5.7.2022 16:29:00 EEST | Business Wire | Press release
Hytera, a leading global provider of professional communications technologies and solutions, together with its subsidiaries Sepura and Teltronic, won awards in 5 categories at the International Critical Communications Awards (ICCAs) 2022 held in Vienna, Austria. The ICCAs, presented by The Critical Communications Association (TCCA), are the most prestigious awards in critical communications celebrating the very best of the sector across a variety of verticals and recognizing those who have made significant and individual contributions to the critical communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005515/en/
Hytera Group Wins Five ICCA Awards in Critical Communications (Graphic: Business Wire)
Hytera was firstly awarded “Best Use of Critical Communications in Transport” for a Sri Lanka Railway (SLR) Telecommunications Project. This project enabled Hytera’s 3GPP-compliant MCS Solution to interconnect the SLR sites and provide railway personnel with real-time access to critical data. This allowed them to better serve passengers and provide a smooth and safe operation for train drivers by improving punctuality and reducing railway accidents.
Sepura also claimed an ICCA award for “Best Use of Critical Communications in Mining, Oil & Gas” for the AutoMate App SPACE Application and SCG22 Mobile Radio which was part of the National Wireless Mining Solution. The solution contributed to the operational performance and safety of staff by enabling radio automation through geo-fencing and situational triggers in iron ore mines in Australia.
The SCU3, Sepura’s latest broadband vehicle device, won “Best MX-C Device of the Year”. This technology aroused considerable interests amongst professional communication users looking for future-proof, powerful data capability to enhance their communications solutions.
Sepura’s Senior Specialist Diana Ball was recognized for her “Outstanding Contribution to Critical Communications” for the development of TETRA standards that are still trusted by users to ensure interoperability between suppliers.
Teltronic’s EDESUR project was next awarded “Best Use of Critical Communications in Utilities”. The NEBULA TETRA infrastructure allowed a private electricity distribution company in Argentina to realize the real-time monitoring and fault detection of a power distribution network, and further improve company management and operational efficiency thanks to Teltronic’s unique SDM (Synchronous Data Management) technology.
In addition to securing these awards, Hytera Group was also shortlisted for a number of additional categories including:
Best MC-X Device of the Year
Hytera PDM680 Rugged MCS Radio
Teltronic RTP-800, the First MCX Cab Radio for Transport
Best MC-X solutions of the year
Sepura SCU3 Broadband Vehicle Device
Best TETRA Device of the Year
Hytera PTC680 Multi-mode Radio
Sepura SCG22 Mobile TETRA Radio
Best Use of Advanced Technology
Hytera AI-based Noise Cancellation for Two-way Radios
Best Use of Critical Communications in Public Safety
Teltronic: RESCAN, Reliability and Maximum Coordination in the Fight against the Volcano
Best Use of Critical Communications in Transport
Hytera: Kazakhstan Railway Runs Safely and Efficiently with TETRA Communications System
Emerging Technology, Product or Solutions
Hytera PNC560, World’s First 5G MCPTT Device
Recently Hytera has released a number of innovations from its wide range of product lines, including the latest H-Series DMR Radios, Body-worn Cameras, PTToC Radios & MCS Radios, Multi-mode Rugged Radio and 5G Xsecure Rugged Device. Also the newly launched Hytera Convergence-Native Solutions (including HyTalk, HyTalk Pro and HyTalk MC), composed of different modules, integrates existing network infrastructures, unifies the network core and the communication platform, and provides open API for new service deployment.
With cutting-edge critical communication technologies, Hytera will continue to bring value to global customers leveraging its technologies and professionals.
For more information about Hytera at ICCAs 2022, please visit: https://www.hytera.com/en/media-center/event/hytera-group-won-international-critical-communication-awards.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005515/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom